Zejula (niraparib) **Prior Authorization Request Form** Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: ME	IEMBER'S FIRST NAME:				
Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.					
MEMBER INFORMATION					
LAST NAME:	FIRST NAME:				
PHONE NUMBER:	DATE OF BIRTH:				
STREET ADDRESS:					
CITY:	STATE: ZIP CODE:				
PATIENT INSURANCE ID NUMBER:					
☐ MALE ☐ FEMALE HEIGHT (IN/CM):	WEIGHT (LB/KG):				
ALLERGIES:					
If you are not the patient or the prescriber, you will need to submit a PHI Disclosure Authorization form with this request which can be found at the following link: primetherapeutics.com/NOPP PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):					
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:					
PRESCRIBER INFORMATION					
LAST NAME:	FIRST NAME:				
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:				
NPI NUMBER:	DEA NUMBER:				
PHONE NUMBER:	FAX NUMBER:				
STREET ADDRESS:					
CITY:	STATE: ZIP CODE:				
REQUESTER (IF DIFFERENT THAN PRESCRIBER):	OFFICE CONTACT PERSON:				

Continued next page



Zejula (niraparib) **Prior Authorization Request Form** Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S LAST NAME: MEMBER'S FIRST NAME:						
MEDICATION OR MEDICAL DISPENSING INFORMATION							
MEDICATION NAME:							
DOSE/STRENGTH:	FREQUENCY:		LENGTH OF THERAPY/REFILLS:		QUANTITY:		
□ NEW THERAPY □ RENEWAL IF RENEWAL, DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES):							
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? YES (IF YES, COMPLETE BELOW) NO							
Medication/Therapy (Spec Drug Name And Dosage):	edication/Therapy (Specify ug Name And Dosage): Duration Of Therapy (Specify Dates):		apy (Specify	Response/Reason For Failure/Allergy:			
2. LIST DIAGNOSES:				ICD-10:			
☐ Fallopian tube cancer							
☐ Primary peritoneal can	cer						
☐ Epithelial ovarian canc	er						
☐ Other diagnosis:							
ICD-10 CODE(S):							
*Please submit documentation.							
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.							
Clinical Information:							
Does patient have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer? Yes No *Please submit chart notes.							
Does patient have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer? Yes No *Please submit chart notes.							
Is the cancer associated with homologous recombination deficiency(HRD-positive) status defined by either (a) or (b): Yes No *Please submit chart notes. (A) Patient's tumor must be positive for deleterious or suspected deleterious germline BRCA mutations, AND/OR (B)Genomic instability							
Is patient's tumor positive for deleterious or suspected deleterious germline BRCA mutations? Yes No *Please submit chart notes.							



Zejula (niraparib) Prior Authorization Request Form Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: M	EMBER'S FIRST NAME:
Has patient had a complete or partial response to a pauling chart notes.	platinum-based chemotherapy? Yes No *Please
Has the patient been previously treated with another $\hfill\square$ Yes $\hfill\square$ No	PARP inhibitor such as Lynparza (olaparib)?
Are there any other comments, diagnoses, symptom information the physician feels is important to this re	
Please note: Not all drugs/diagnosis are covered on required information is received.	all plans. This request may be denied unless all
	rue and accurate to the best of my knowledge. I oup or its designees may perform a routine audit and the accuracy of the information reported on this form.
Prescriber Signature or Electronic I.D. Verification:	Date:
information that is legally privileged. If you are not the disclosure, copying, distribution, or action taken in a	canying this transmission contain confidential health ne intended recipient, you are hereby notified that any reliance on the contents of these documents is

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909



return FAX) and arrange for the return or destruction of these documents.